Heavy menstrual bleeding is prolonged (>7 days) or excessive (>10 mL) uterine bleeding occurring at regular intervals over several menstrual cycles.
It is menstrual blood loss that is excessive and interferes with patient's physical, emotional, social and quality of life.
It is also referred to as menorrhagia or hypermenorrhea.
It is a common problem in women of reproductive age that usually causes anemia.
Uterine fibroids and polyps are the most common pathology identified.
New drug applications approved by US FDA as of 16-31 May 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Use of a levonorgestrel intrauterine device (IUD) can help reduce menstrual bleeding in adolescents with disabilities — thus providing an option for menstrual management in this population with special needs, in whom data on IUD use are lacking.
Combining the oral GnRH* receptor antagonist relugolix together with oestradiol and the progestin norethindrone helps protect against bone loss induced by oestrogen deprivation associated with the use of GnRH receptor antagonist monotherapy for treating heavy menstrual bleeding, according to the LIBERTY studies released during the ACOG 2020 Meeting.
Thalassaemia becomes a global health problem. Most women with thalassaemia trait can be picked up by universal prenatal screening for thalassaemia using mean corpuscular volume/haemoglobin, followed by haemoglobin pattern with or without DNA analysis.